NASDAQ:TXG - 10x Genomics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $181.44
  • Forecasted Upside: 16.62 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$155.58
▲ +8.18 (5.55%)
1 month | 3 months | 12 months
Get New 10x Genomics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TXG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TXG

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$181.44
▲ +16.62% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for 10x Genomics in the last 3 months. The average price target is $181.44, with a high forecast of $240.00 and a low forecast of $105.00. The average price target represents a 16.62% upside from the last price of $155.58.
Buy
The current consensus among 7 investment analysts is to buy stock in 10x Genomics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/14/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/13/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/12/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/10/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/7/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/5/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/7/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/25/2021CitigroupBoost Price TargetBuy$195.00 ➝ $240.00High
i
2/25/2021JPMorgan Chase & Co.Boost Price TargetOverweight$160.00 ➝ $195.00Medium
i
2/25/2021CowenBoost Price TargetOutperform$155.00 ➝ $200.00Medium
i
2/25/2021Morgan StanleyBoost Price TargetOverweight$145.00 ➝ $215.00High
i
2/18/2021CitigroupBoost Price Target$195.00 ➝ $240.00High
i
2/18/2021CowenBoost Price TargetOutperform$155.00 ➝ $200.00Medium
i
2/18/2021JPMorgan Chase & Co.Boost Price TargetOverweight$160.00 ➝ $195.00Medium
i
12/16/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target$165.00 ➝ $195.00Low
i
12/16/2020Smith Barney CitigroupBoost Price Target$165.00 ➝ $195.00Low
i
12/2/2020The Goldman Sachs GroupInitiated CoverageNeutral$150.00Medium
i
11/11/2020Smith Barney CitigroupBoost Price Target$120.00 ➝ $165.00Low
i
11/11/2020Morgan StanleyBoost Price TargetOverweight$135.00 ➝ $145.00High
i
9/16/2020Bank of AmericaBoost Price TargetBuy$109.00 ➝ $138.00Medium
i
9/15/2020JPMorgan Chase & Co.Boost Price TargetOverweight$110.00 ➝ $140.00Low
i
9/9/2020Morgan StanleyInitiated CoverageOverweight$135.00High
i
8/12/2020JPMorgan Chase & Co.Boost Price TargetOverweight$95.00 ➝ $110.00High
i
7/20/2020Bank of AmericaBoost Price TargetBuy$91.00 ➝ $105.00Low
i
7/9/2020Stifel NicolausInitiated CoverageBuy$105.00Medium
i
5/12/2020CitigroupBoost Price TargetBuy$90.00 ➝ $100.00High
i
5/12/2020JPMorgan Chase & Co.Boost Price TargetOverweight$90.00 ➝ $95.00High
i
5/12/2020CowenBoost Price TargetOutperform$68.00 ➝ $85.00Medium
i
4/20/2020CitigroupBoost Price TargetBuy$75.00 ➝ $90.00Medium
i
3/20/2020CitigroupLower Price TargetBuy$100.00 ➝ $75.00High
i
3/5/2020GuggenheimInitiated CoverageBuy$96.00High
i
2/19/2020JPMorgan Chase & Co.Reiterated RatingOverweight$65.00 ➝ $95.00High
i
1/6/2020CitigroupInitiated CoverageBuyLow
i
12/20/2019Evercore ISIInitiated CoverageBuy$62.00N/A
i
Rating by Luke Sergott at Evercore ISI
10/7/2019CowenInitiated CoverageOutperform$55.00Medium
i
10/7/2019Bank of AmericaInitiated CoverageBuy$62.00Medium
i
10/7/2019JPMorgan Chase & Co.Initiated CoverageOverweight$55.00Medium
i
9/24/2019Evercore ISIInitiated CoverageOutperform$70.00High
i
(Data available from 3/7/2016 forward)
10x Genomics logo
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. Its company offers chromium instruments, enzymes, microfluidic chips, slides, reagents, and other consumable products. The company's single cell solution runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics, including the physical organization of DNA; single cell CNV for measuring cellular heterogeneity through DNA changes, such as copy number variation; and visium spatial gene expression solution that measures the spatial gene expression patterns across a tissue sample. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10X Genomics, Inc. in November 2014. 10x Genomics, Inc. was founded in 2012 and is headquartered in Pleasanton, California.
Read More

Today's Range

Now: $155.58
$140.85
$157.04

50 Day Range

MA: $181.87
$147.40
$196.86

52 Week Range

Now: $155.58
$48.78
$201.70

Volume

1,612,320 shs

Average Volume

786,547 shs

Market Capitalization

$15.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39

Frequently Asked Questions

What sell-side analysts currently cover shares of 10x Genomics?

The following sell-side analysts have issued reports on 10x Genomics in the last year: Bank of America Co., Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, JPMorgan Chase & Co., Morgan Stanley, Smith Barney Citigroup, Stifel Nicolaus, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for TXG.

What is the current price target for 10x Genomics?

9 Wall Street analysts have set twelve-month price targets for 10x Genomics in the last year. Their average twelve-month price target is $181.44, suggesting a possible upside of 16.6%. Citigroup Inc. has the highest price target set, predicting TXG will reach $240.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $105.00 for 10x Genomics in the next year.
View the latest price targets for TXG.

What is the current consensus analyst rating for 10x Genomics?

10x Genomics currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TXG will outperform the market and that investors should add to their positions of 10x Genomics.
View the latest ratings for TXG.

What other companies compete with 10x Genomics?

How do I contact 10x Genomics' investor relations team?

10x Genomics' physical mailing address is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. The company's listed phone number is 925 401 7300 and its investor relations email address is [email protected] The official website for 10x Genomics is www.10xgenomics.com.